A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity

, and HIV tier 2 neutralizing antibodies in nonhuman primates. Together, these findings shed new light on mechanisms by which saponin adjuvants act to promote the immune response and suggest that SMNP may be a promising adjuvant in the setting of HIV, SARS-CoV-2, and other pathogens.

A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity | Litlas